Advertisement

Current Diabetes Reports

, 19:141 | Cite as

Human Endogenous Retroviruses and Type 1 Diabetes

  • Sandrine LevetEmail author
  • B. Charvet
  • A. Bertin
  • A. Deschaumes
  • H. Perron
  • D. Hober
Open Access
Pathogenesis of Type 1 Diabetes (A Pugliese and SJ Richardson, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Pathogenesis of Type 1 Diabetes

Abstract

Purpose of the Review

The aim of this review is to discuss recent data pointing at an involvement of human endogenous retroviruses (HERVs) in type 1 diabetes (T1D) onset and progression.

Recent Findings

The envelope protein of HERV-W family, named HERV-W-Env, was detected in pancreata from T1D patients and was shown to display pro-inflammatory properties and direct toxicity toward pancreatic beta cells.

Summary

The etiopathogenesis of T1D remains elusive, even if conventional environmental viral infections have been recurrently involved. Nonetheless, a new category of pathogens may provide the missing link between genetic susceptibility and environmental factors long thought to contribute to T1D onset. A number of studies have now shown that HERV sequences, which are normally inactivated or repressed in the human genome, could be activated by environmental viruses. Thus, if similarly activated by viruses associated with T1D, disregarded HERV genes may underlie T1D genetic susceptibility. Moreover, once expressed, HERV elements may display broad pathogenic properties, which identify them as potential new therapeutic targets.

Keywords

Endogenous retrovirus Type 1 diabetes HERV Enterovirus Coxsackievirus B4 

Introduction

The etiopathogenesis of some diseases has remained elusive, particularly for those involving a complex interplay between environmental and genetic factors, such as autoimmune diseases. Past decades have witnessed the development of a new comprehensive approach for these multifactorial diseases, which involves the study of a new kind of pathogenic elements: human endogenous retroviruses (HERVs). In the current state of knowledge, HERV may fill the gap between environmental factors, genetic factors, and pathogenic mechanisms of diseases such as multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS), only quoting the most studied ones in this HERV paradigm. This review will address HERV biology, introduce their involvement in MS and ALS, and will then focus on the evidence suggesting a role for HERV in type 1 diabetes (T1D).

A Disregarded Moiety of Human Genome May Enlighten the Etiopathogenesis of Some Autoimmune and Neurogenerative Diseases

Mobile Genetic Elements and HERV

Nearly half of the human genome is composed of remnants from mobile genetic elements, which were considered as “junk DNA” at the dawn of genome sequencing. These elements are vestiges of ancient viral infections that occurred million years ago [1••]. Mobile genetic elements encompass transposons and retrotransposons, based on the intermediate used to integrate into the genome, DNA or RNA respectively [2, 3]. HERVs belong to the retrotransposon group and display LTR (long terminal repeats) at their extremities, which are regions involved in chromosomal retro-integration and in regulation of transcription [1, 4].

HERVs were generated by a process called “endogenization.” This happened when environmental retroviruses infected the germinal cells of hosts during evolution, leading to their transmission into the genome of the progeny and to next generations (Fig. 1). Owing to molecular properties of retroviral ancestors, HERVs are subjected to intra-genomic dissemination through retrotransposition and recombination, thus creating multiple copies of HERV genes [5]. Moreover, multiple new infections over very long periods of species evolution caused re-entries in the genomes of certain individuals, thus generating genomic diversity with newly integrated copies [6]. As a consequence, HERVs account for approximately 8% of the human genome, although most HERV copies are inactivated by mutations, deletions, or silenced by epigenetic modifications (Fig. 1) [1••].
Fig. 1

Endogenization of retroviruses during evolution. The upper panel depicts the successive steps leading to the stable insertion of environmental viral RNA into the genome of species. ❶ This process, called endogenization, starts from the infection of germ cells leading to the integration of the provirus into a chromosome. ❷ Fertilization with one of these infected cells will result in an individual harboring the provirus in each of its cells, both germinal and somatic. The provirus will then be transmitted to the offspring of this individual. ❸ Other environmental retroviruses can simultaneously undergo a comparable endogenization process, ❹ eventually leading to multiple and variable copy number in the final population. The lower panel illustrates some of the evolution options of a provirus once integrated into chromosomal DNA. ❺ Most of ERV copies will become defective, due either to mutations, deletions or insertions. ❻ For copies retaining protein coding potential, processes of epigenetic silencing, such as methylation, normally suppress transcriptional activity. ❼ Alongside the neutralization of the provirus described above, the evolution sometimes takes advantage of a viral function to enrich the physiological functions of the host. A well-known example is Syncytin-1 protein, which derives from an HERV-W envelope protein harboring fusogenic activity. Syncytin-1 is expressed during placentation and is required for trophoblast cells fusion into a multinucleated syncytiotrophoblast layer, a critical step of placental development

With nearly two decades hindsight, it appeared that HERV copies are not mere “junk DNA.” Some of them have been domesticated and now belong to the pool of physiological genes, such as Syncytin-1 involved in placentation, while others have retained pathological properties when abnormally activated (Fig. 1).

Activation of HERV

The prerequisite for an effective transcription is that HERV sequences must retain a functional LTR, not have major deletions and/or nucleotide substitutions, and must be epigenetically de-repressed. If these conditions are met, both micro- and macro-environmental triggers may activate HERVs.

Epigenetic Control

HERV activation is linked to the chromatin state where the provirus is located (Fig. 2) [1••]. DNA methylation and histone modifications are key factors in the epigenetic control of the transcription of human genes as well as of HERV elements. EBV (Epstein Barr virus) and CMV (cytomegalovirus) have been shown to demethylate HERV sequences, thereby unlocking their epigenetic silencing [7, 8] and further allowing activation of normally “non-responding” copies when triggered by later occurrence of transactivating events.
Fig. 2

Dysregulation of epigenetic control and HERV transactivation by Herpesviridae. Mechanisms of transactivation by herpesviruses are exemplified with EBV (Epstein Barr virus), HSV-1 (herpes simplex type 1), HHV-6 (human herpesvirus 6), and HCMV (human cytomegalovirus). ❶ HERV copies are normally not accessible to transcription thanks to DNA methylation and to other mechanisms of epigenetic control. Herpesviruses can impair the methylation process, either by inhibiting methytransferases as shown for LMP-2A (latent membrane protein 2A) from EBV, or by sequestrating methyltransferases within the cytoplasm as shown for IE (immediate early) protein from HCMV. ❷ ICP0 (infected cells polypeptide 0) viral protein from HSV-1 were described to activate HERV-W LTR, thereby activating initiation of transcription. ❸ Upon binding of EBV and HHV-6 on their receptors, CD21 and CD46 respectively, signaling pathways activation leads to the transcription of HERV-W

Environmental Viruses

Environmental viruses have been shown to directly transactivate HERV elements in several studies (Fig. 2). HERV genes and/or reverse transcriptase (RT) activity are activated in various human cell types by Herpesviridae, including HSV-1 (herpes simplex virus type-1) [9, 10], VZV (varicella-zoster virus) [9], CMV [11], HHV-6 (human herpes virus type 6) [12], and EBV [13, 14]. EBVgp350 protein activated HERV-W in B cells and monocytes, but not in T cells or NK cells [14]. Thus, many viruses that have not previously been indicated as causative agents of autoimmune diseases were shown to trigger activation of HERVs, which in return may activate well-known pathogenic cascades in diseases such as MS, T1D, and ALS.

Inflammatory Stimuli

Inflammatory stimuli may activate epigenetically dysregulated HERV. Transcription of already activated HERV-W sequences may be upregulated by pro-inflammatory cytokines such as IL-6 (interleukin 6) and TNF-α (tumor necrosis factor alpha) [15], but are inhibited by IFN-β (interferon beta) [16] .

Drugs and Toxins

Antipsychotic drugs have been associated with activation of HERV transcription. Valproic acid, for example, may activate HERV-W transcription in human glioblastoma cell line SK-N-SH [17] and a pesticide named dieldrin may also activate HERV-driven enhancers in human T cells [18].

As described above, environmental factors have the ability to activate HERV copies otherwise hidden and silenced in the human genome. The consequence of this process can be deleterious and may result in diseases as exemplified with MS and ALS, in the forthcoming section.

Examples of Best-Studied Associations Between HERV and Human Diseases

HERV-W and Multiple Sclerosis

MS provides an example of an autoimmune and neurodegenerative disease whose etiopathogenesis has recently been made more comprehensive by the discovery of the involvement of HERV. MS is an inflammatory disease of the central nervous system, causing myelin destruction and oligodendrocytes demise, followed by axonal disruption, neurodegeneration, and increasing disability. The etiology of MS lies somewhere at crossroads between genetic predisposition [19] and environmental factors, such as infectious mononucleosis and smoking [20].

Several HERV families have been linked to MS, including HERV-K, HERV-H, and HERV-W. However, a recent meta-analysis concluded that the most compelling association is with HERV-W [21]. HERV-W env and pol RNA have been detected in serum and PBMC (peripheral blood mononuclear cell) of MS patients [22, 23], and the presence in the CSF (cerebrospinal fluid) was associated with a poor prognosis of the disease [24]. HERV-W protein expression in active lesions has been detected in macrophages, astrocytes, and in endothelial cells of neighboring blood vessels [25], but was predominantly observed in microglial cells, the cell type driving the process leading to axonal demyelination, lesion expansion, and neurodegeneration [26••].

HERV-W-Env pathogenic functions have also been implicated both in inflammatory processes and in direct cytopathic effects affecting non-immune cells [26••]. HERV-W-Env induced the secretion of pro-inflammatory cytokines in vitro by human immune cells, a process requiring TLR4 (Toll-like receptor 4) activation [27]. In vivo, HERV-W-Env promoted anti-myelin autoimmunity leading to experimental autoimmune encephalomyelitis [28••] and elevated pro-inflammatory cytokine production upon systemic injection in mice [27]. HERV-W-Env was also found to mediate TLR4-dependent effects in non-immune cells such as oligodendrocytes precursor cells (OPC), which are prevented from differentiating upon HERV-W-Env exposure, thereby precluding their remyelinating functions [29]. Thus, converging data have identified the pathogenic protein HERV-W-Env as a therapeutic target in MS, and have prompted the clinical development of temelimab (formerly GNbAC1), a humanized monoclonal IgG4 antibody targeting HERV-W-Env [30, 31]. For the first time in human therapeutics, this new drug is targeting a HERV protein, which could represent an upstream pathogenic driver leading to MS. Temelimab has already demonstrated an excellent safety profile and promising results in neuroprotection and in myelin preservation in a phase II clinical trial (NCT03239860) [26••, 30].

This example of HERV-W and MS illustrates how fundamental research can lead to new therapeutic strategies. In MS, approved drugs mainly consist of immunomodulatory agents, the efficacy of which has only been shown to alleviate relapses of early symptoms in most MS cases, but were shown to be ineffective at stalling disease progression. The involvement of HERV-W has open new therapeutic avenues addressing unmet needs, since acting on pathogenic mechanisms involved in lifelong disease progression, demyelination, and neurodegeneration [26••, 30].

HERV-K and Amyotrophic Lateral Sclerosis

ALS is another example of how a complex disease of unknown etiology can be analyzed from a new point of view thanks to the demonstration of HERV-K involvement in its pathogenesis, thereby unveiling a new pathogenic target for this rapidly fatal disease.

ALS is a neurodegenerative disorder primarily affecting motor neurons, leading to severe motor disabilities and eventually to death, mainly from ventilatory failure within 2 to 3 years following symptoms onset [32]. Two main forms of the disease are described, a familial form and a sporadic form. Genetic mutations are causative in familial forms accounting for about 10% of ALS patients. For the 90% of ALS patients affected by the sporadic form, the etiology of the disease remains elusive. Hypotheses have incriminated environmental factors including smoking and exposure to agricultural chemicals and heavy metals [33]. Infections from exogenous viruses have also been considered as a risk factor for developing ALS, such as herpesvirus and enterovirus infections [33]. However, none of these environmental factors have been definitively shown to be a causative factor, either because of the scarcity of the data or because of conflicting results [33].

ALS has recently been associated with HERV-K, and particularly with its envelope protein HERV-K-Env. HERV-K transcripts and proteins have been detected in human ALS brain tissue, as well as reverse transcriptase activity in blood [34, 35]. In vitro, HERV-K-Env induced neurotoxicity and its expression in human neurons caused inhibition of neurite growth and cell death [35]. Transgenic mice expressing the HERV-K-Env displayed volume loss in the motor cortex and decreased activity in pyramidal neurons, while they developed progressive motor dysfunction mimicking the clinical presentation of human ALS [35].

Concerning the activation of HERV-K expression in ALS, pro-inflammatory cytokines such as TNF-α have been shown to enhance HERV-K transcription and protein production in human astrocytes and neurons [36]. Mechanistically, the presence of functional ISREs (interferon-stimulated response elements) in HERV-K LTR allows the binding of NF-κB (nuclear factor kappa B) and IRF1 (interferon regulatory factor 1), further driving the activation of transcription [36, 37].

As presented in this section with best-studied examples to date, the involvement of HERV in diseases of formerly unknown etiology has brought new paradigms for tackling such disorders. The next part of this review will examine evidence that HERV is involved in the pathogenesis of type 1 diabetes, which could open up new therapeutic opportunities for treatment.

The Elusive Etiology of T1D: an Interplay Between Environmental Viruses and HERV?

T1D and Environmental Viruses

Detection of the Virus Per Se in T1D Patients

Several environmental viruses have already been associated with T1D, but most of the results were later challenged or are still awaiting confirmation. The most robust association between T1D and environmental viruses relates to enteroviruses, and especially to coxsackieviruses B (CV-B). Enterovirus potentially interact with several receptors [38], among which CAR (coxsackie adenovirus receptor) is the most studied in the T1D context. Enteroviruses are able to infect pancreatic islets via CAR, which is expressed on beta cells and alpha cells, and are able to replicate in both of these cell types [39, 40]. However, histology studies have mainly detected the VP1 (viral protein 1) capsid protein in pancreatic beta cells [41, 42]. The association between enteroviral infection and T1D has also been observed in many instances by molecular and immunological techniques in various biological samples, especially in the blood compartment and in the pancreas [42, 43, 44]. Thus, the presence of enteroviruses in T1D patients was observed by multiple groups, with different techniques and in several human tissues.

Detection of Viral Sensors and Antiviral Signature in T1D Patients

Upon virus entry or when exposed to viral molecules, cells will mount responses starting by the detection of the infection. PKR (protein kinase R) and MDA5 (melanoma differentiation–associated protein 5) are involved in viral RNA sensing. PKR has been detected in islets of T1D patients where it co-localizes with VP1 expression [41, 45], and single nucleotide polymorphisms within the gene encoding MDA5 have been found associated with higher risk of developing T1D [46]. The transcription factor STAT-1 (signal transducer and activator of transcription 1), which is involved in antiviral response, has also been found to be upregulated in insulin-containing islets of T1D [47]. Of note, STAT-1 expression is strongly correlated with hyperexpression of HLA Class I antigens, a characteristic feature of T1D pathogenesis [47]. Antiviral antibodies against EBV antigens have also been found to be associated with T1D in an immunoproteomic array profiling antiviral antibodies targeting 23 viral strains [48]. In this study, antiviral antibodies against 646 viral antigens were screened using a high-throughput immunoproteomics approach in patients with new-onset T1D. Among the viral strains tested were the six exogenous viruses epidemiologically associated with T1D (CMV, EBV, CV-B, rubella virus, mumps virus, and rotaviruses) and the endogenous retrovirus HERV-K [48].

Thus, the detection of recent or past viral infections, either directly or indirectly as described above, has provided converging evidences of particular infectious profiles in T1D patients [49••]. However, whether enteroviruses, or possibly other viruses like EBV, are inducers or aggravating factors of T1D is still an open question. The next paragraph will examine pathogenic mechanisms affecting pancreatic cells upon viral infection.

Involvement of Viral Infection in T1D Pathogenesis

An interplay between enteroviruses, innate and adaptive immunity may result in various mechanisms by which environmental viruses can contribute to T1D development [50••].

Direct Pancreatic Insults Following Enteroviral Infections

Human pancreatic islets, and beta cells in particular, can sustain a persistent CV-B infection [51]. Enteroviral infections were reported to induce beta cell death, decrease in insulin mRNA expression and insulin secretion and disruption of Golgi apparatus [52, 53]. In vitro, ductal cells can also be persistently infected with the diabetogenic CV-B4 strain (CV-B4 E2) thus impairing the differentiation of precursor endocrine cells and disturbing the microRNA expression profile [54, 55••].

Innate Immune Cells Entanglement in Deleterious Effects of Enteroviral Infections

Monocytes and macrophages are major target cells of enteroviruses, which upon infection induce expression of interferons and pro-inflammatory cytokines such as TNF alpha and IL-6 [56, 57, 58••]. Beta cells are particularly sensitive to interferons, which can induce ER stress, reduce insulin content, increase proinsulin to insulin ratio, and decrease expression of PC1 (proinsulin convertase 1) and PC2 (proinsulin convertase 2) enzymes responsible for maturation of proinsulin into insulin [59]. The pro-inflammatory state of beta cell resulting from viral infection is then amplified by the recruitment and activation of monocytes and dendritic cells, the secreted chemokines and cytokines of which will participate to the recruitment of T cells, including autoreactive clones [60, 61].

Peculiar Role of Facilitating Antibodies

Following the initial contact of a virus with a host, antibodies targeting the invader will be produced upon activation of the adaptive immune system. Unfortunately, some of these antibodies will not prevent a subsequent infection, but will rather increase it [62••]. This phenomenon is termed ADE (antibody-dependent enhancement) and relies on so called “facilitating antibodies.” Facilitating antibodies targeting the CV-B VP4 (viral protein 4) capsid protein have been detected in T1D patients and were reported to enhance the infection of monocytes and macrophages by CV-B4, which could promote dissemination of the virus to the pancreas [63, 64, 65]. The infection of monocytes and macrophages with CV-B4 in the presence of facilitating antibodies was shown to induce the production of IFN-α (interferon alpha), which can stimulate the presentation of autoantigens from local tissue lesions, and the secretion of pro-inflammatory cytokines [66, 67, 68]. The pathogenic effects of facilitating antibodies have also been observed in mice, in which anti-CV-B4 facilitating activity of the serum was observed upon the inoculation of CV-B4 [69]. Mice that were subsequently re-infected with this virus presented elevated blood glucose level and pancreas damage. This correlated with an increased viral load of the pancreas, compared with controls [70]. The ADE process enhancing, or even allowing, the infection of monocytes and other cell types may represent a critical step for a significant contribution of enterovirus to the pathogenesis of T1D [62••].

However, commonly described consequences of environmental virus infections, including the direct detrimental effect on beta cells and the potential indirect stimulation of autoimmunity, still do not provide a comprehensive understanding of the natural history of T1D with a prodromal period, a rather sudden clinical onset and a lifelong variable evolution. Thus, a causal evidence between environmental viruses and T1D remains elusive, seemingly indirect or requiring complementary effects from other pathogenic factors. Relevant to this matter, it is now well established that environmental factors such as viral infections may trigger the expression of HERV proteins. In the next sections, we will discuss how HERV may represent the missing link at the genetic interface between (i) environmental factors such as viruses and (ii) downstream activation of pathways resulting in T1D onset and progression.

T1D and Endogenous Retroviruses

Genetic predisposition and numerous environmental factors, including viruses, appear to contribute to T1D pathogenesis [71]. In the absence of direct causal evidence between these contributing factors and beta cell destruction, HERV elements opened a new avenue of research with their unique positioning in the human genome and their interactions with environmental factors, particularly viruses. The current section will explain (i) how HERV could be transactivated in a T1D context, (ii) the animal evidences of ERV (endogenous retrovirus) involvement in disease pathogenic mechanisms, and finally (iii) the potential contribution of HERV in human T1D.

Transactivation of HERV by Exogenous Viruses in a T1D Context

Among the viruses that have been associated with T1D, even with low degree of confidence, only EBV has so far been described to transactivate HERV copies. As mentioned above, among 23 viral strains, only antiviral antibodies against EBV antigens have been found to be associated with T1D patients [48]. In parallel, EBV is described to transactivate both HERV-K18 and HERV-W [13, 14]. In particular, the EBVgp350 protein was shown to activate HERV-W in B cells and monocytes [14]. Moreover, EBV is able to demethylate DNA, thereby unlocking the epigenetic silencing of HERV [8]. Enteroviruses may also be involved in HERV transactivation, which is currently under investigation.

Animal Studies

Several studies reported an association between endogenous retroviruses and T1D pathogenesis in NOD mice. ERV copies, proteins, and particles have been observed in beta cells from NOD mice and have been suggested to be involved in this T1D mouse model [72, 73, 74]. Since these early reports, it has been shown that NOD mice developed autoantibodies against ERV envelopes proteins, with antibody titers increasing with age and disease progression [75••]. ERV proteins encoded by the gag gene (retroviral capsid proteins) also appeared to be involved in pro-inflammatory responses and in the induction of autoreactive T cells in NOD mice [75••].

Apart from the few evidences linking ERV to T1D in the NOD mouse model, two human endogenous retroviruses, HERV-K and HERV-W, have been presented as abnormally expressed in human T1D.

HERV-K

A low number of HERV-K copies within the C4 gene cluster of T1D patients’ genome has been linked to an increased risk of developing T1D. “Missing” protective endogenous retroviral insertions may thus suppress genetic factors of resistance against T1D [76]. Such protective endogenous retrovirus copies are well known in families of animal ERV and were shown to provide protection against infections by related retroviruses [77]. Antibodies directed against a peptide of HERV-K6 envelope protein have also been found elevated in a Polish cohort of young T1D patients [78]. HERV-K18 was claimed to be associated with T1D in human [79, 80], but this has later been disproved by successive studies [81, 82, 83, 84]. Conrad and colleagues had described an endogenous retroviral sequence, termed IDDMK(1,2)22 and related to HERV-K18 family, encoding a protein with superantigen characteristics in T1D patients [80]. However, it turned out that the PCR-amplified sequences attributed to T1D probably came from genomic DNA contamination [81, 82, 83]. Still, an association between HERV-K18 polymorphisms and T1D was later reported [79] but was also subsequently rebutted [84].

HERV-W

The most compelling evidence for a functional association between HERV and T1D has been shown for HERV-W. The study of this endogenous retrovirus was initiated by the isolation of retroviral particles from MS patients [85]. Subsequent studies revealed that these particles originated from HERV elements, first termed multiple sclerosis associated retrovirus (MSRV). This prototype MSRV sequence later unveiled multiple copies of a previously unknown HERV family, now named HERV-W since using tryptophane (W) tRNA as a primer for reverse transcription [86].

The envelope protein of HERV-W, termed HERV-W-Env, has been detected in T1D patients and particularly in pancreatic acinar cells located in the vicinity of pancreatic lesions of T1D patients [87••]. Immunohistology of pancreata from nPOD repository suggested a spreading of HERV-W-Env expression paralleling disease progression and/or duration [87••], as already shown in MS post-mortem brains [25]. Antibodies directed against a peptide of HERV-W-Env have also been detected in serum of youths at risk for T1D and youths affected by T1D [78]. It appeared that elevated levels of these anti-HERV-W-Env antibodies overlapped with or preceded the appearance of conventional T1D autoantibodies (ICA, IAA, IA2A, and/or GADA) [78]. It has been observed that HERV-W-Env promoted macrophages recruitment within the pancreas and beta cell dysfunction, as shown by the inhibition of insulin secretion by HERV-W-Env in primary cultures of human islets of Langerhans [87••]. Of note, beta cells express TLR4 [88, 89] and HERV-W-Env exerts its pathogenicity through interaction with TLR4 [27].

Activation of TLR4 by chronically expressed HERV-W-Env is particularly intriguing in a T1D perspective. The stimulation of TLR4 has already been described to inhibit insulin secretion, to decrease beta cell viability and expression of PDX-1 and Maf-A, two critical transcription factors required for beta cell function [88, 89]. Additionally, downstream elements of TLR4 signaling are upregulated in T1D patients, such as NF-κB, MyD88, and TRIF [90].

Apart from its deleterious effects on beta cells, HERV-W-Env displays other pathogenic properties that may be relevant in T1D pathogenesis. In particular, HERV-W-Env impairs TLR4-expressing cells such as endothelial cells [91] and Schwann cells [92], both cell types whose dysfunction is associated with major T1D comorbidities. Moreover, a functional implication of HERV-W in immune processes has been evidenced. Pro-inflammatory cytokines expression was induced in monocytes upon stimulation with HERV-W-Env through TLR4 receptor activation, while dendritic cells were elicited to support a Th1-like type of T-helper lymphocyte differentiation [28••, 93, 94]. Likewise, HERV-W-Env has been shown to induce T cell responses with superantigen characteristics [95], which would provide an explanation for in vivo promotion of autoimmunity [28••].

The particular HERV-W-env genomic copy encoding the pathogenic HERV-W-Env protein involved in T1D remains to be identified. This identification is precluded by extensive interindividual variations existing in the proviral content of some HERV families in human genomes [96]. Such non-ubiquitous copies or somatic DNA rearrangements in chromosomal HERV sequences may explain difficulties to pinpoint the relevant copy in DNA databases of reference human genomes [96]. The identification of a peculiar HERV copy clustering with T1D, or T1D subtypes, would allow the identification of a potentially critical genetic risk factor that could not have been pinpointed from traditional genetic studies in which this part of the human DNA is not examined with appropriate methods required for multicopy transposable elements [4, 96••].

From the data presented in this review, it appeared that HERV-W-env could contribute to the genetic susceptibility to T1D and MS as encoding a key player at the gene-environment interface of their respective pathogenesis. Whether the genomic copies involved in the two diseases are identical or different has to be determined, but most of epidemiological studies about T1D and MS co-occurrence found higher prevalence rates than expected for one disease alone [97]. This observation contradicts studies on HLA risk haplotypes for MS that are protective from T1D [97]. This would be compatible with a dominant effect of the HERV-W factor over the HLA phenotype in a multiparametric equation predicting disease susceptibility. Within this equation, if HERV-W-env genomic copies involved in T1D and MS are identical, then the question of the disease onset in an organ instead of the other is raised. The virus tropism for the intestine and the pancreas (Enteroviruses) or for the central nervous system (Herpesviruses) could determine a local autoimmune reaction and a local direct toxicity occurring in the pancreas or in the brain, via HERV-W-Env transactivation.

Altogether, these data provide substantial arguments to consider HERV-W-Env at the interface between genetic susceptibility, environmental factors, and downstream pathogenic cascades leading to T1D. Figure 3 presents a scenario for the potential contributions of exogenous viruses and HERV into T1D pathophysiology. Briefly, particular HERV-W-env genomic copies could be activated by environmental infections, potentially recurrent and requiring an ADE facilitating process. Once activated and produced, HERV-W-Env protein would affect several targets, such as pancreatic beta cells, immune cells, and other TLR4-positive cells. This unique positioning identifies HERV-W-Env as a new therapeutic target in T1D. A phase IIa clinical trial addressing HERV-W-env-neutralizing humanized antibody temelimab clinical safety and pharmacokinetics endpoints in T1D adults patients has recently been conducted (ClinicalTrials.gov Identifier: NCT03179423) [98]. It has confirmed the very strong safety profile of temelimab and now calls for further clinical developments in recent-onset T1D pediatric patients.
Fig. 3

Global model depicting HERV-W-Env involvement in T1D onset and progression. Central to this model is the detection of HERV-W-Env, either locally in pancreatic acinar cells, or in systemic circulation (expressed by PBMC or present in a soluble form in blood) [87••]. Whether the soluble form of HERV-W-Env arises from pancreas or immune cells remains to be determined. ❶ In this model, EBV infection could be an early global priming event of immune cells. Accordingly, anti-EBV antibodies have been detected in T1D patients [48], and EBV can dysregulate epigenetic control [8], thereby rendering genomic region bearing HERV copies accessible to transcription [14]. ❷ Later in individual’s life, an enteroviral infection may activate directly HERV-W in the pancreas or in immune cells previously primed and harboring newly accessible DNA regions. The transactivation of HERV-W-Env by enteroviruses is a hypothesis currently under investigation. ❸ Involvement of enteroviral infection may be reinforced by the ADE (antibody-dependent enhancement) process and the production of facilitating antibodies, which increase enteroviral infection in monocytes and macrophages, resulting in infection spreading to the pancreas [50••]. ❹ HERV-W-Env transactivation and expression could occur in pancreatic acinar cells, ❺ resulting in inhibition of insulin secretion and macrophages recruitment within the pancreas [87••]. ❻ HERV-W-Env promotes pro-inflammatory cytokine production by immune cells [27] and its expression could occur in mononuclear cells thereby participating in increased circulating levels of HERV-W-Env in blood [14]. ❼ HERV-W-Env also exerts detrimental effects on endothelial cells [91] and Schwan cells [92], suggesting a possible implication in T1D-associated comorbidities. ❽ Altogether, these pathogenic effects argue for an involvement of HERV-W-Env in T1D onset and progression

Conclusion

The present review discussed the largely disregarded aspects of HERV multicopy elements which may be dysregulated by epigenetic changes and transactivated by environmental triggers, possibly resulting in autoimmune diseases such as T1D and MS, or degenerative diseases such as ALS.

In this scenario, successive events would link external stimuli, like enteroviruses in the case of T1D, to pathological cascades associated with HERV elements in susceptible tissues. This would provide possible solutions to the multifactorial equation of these complex diseases and this has already prompted different groups to evaluate novel therapeutic approaches in patients with MS or T1D, in which HERV-W is involved [99] or in patients with ALS in which HERV-K is involved [100].

This area of research is rapidly evolving and it is likely that HERVs, representing about 8% of the human genome, may contribute to T1D and other complex and multifactorial human diseases. The therapeutic approaches targeting toxic proteins expressed by HERVs may thus offer completely novel perspectives of treating upstream pathogenic factors without affecting downstream dysregulated physiological functions.

Notes

Funding Information

Studies about enteroviruses from D.H. mentioned in this review were supported by Ministère de l’Education Nationale de la Recherche et de la Technologie, Université de Lille (Equipe d’accueil 3610), Centre Hospitalier et Universitaire de Lille, and by EU FP7 (GA-261441-PEVNET). A.B. was supported by a scholarship of Université de Lille.

Compliance with Ethical Standards

Conflict of Interest

A. Bertin, A. Deschaumes, and D. Hober declare no conflict of interest.

S. Levet and B. Charvet receive compensation for their work at GeNeuro Innovation.

H. Perron receives compensation for his work at GeNeuro Innovation and is inventor on patents owned by bioMérieux, INSERM, or GeNeuro but has transferred all his rights to bioMérieux or to GeNeuro under applicable laws for employed inventors.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Feschotte C, Gilbert C. Endogenous viruses: insights into viral evolution and impact on host biology. Nat Rev Genet 2012;13(4):283–96. doi: https://doi.org/10.1038/nrg3199. A global review on viral sequences having entered the genome of species and their biological effects. CrossRefGoogle Scholar
  2. 2.
    Hancks DC, Kazazian HH Jr. Roles for retrotransposon insertions in human disease. Mob DNA. 2016;7:9.  https://doi.org/10.1186/s13100-016-0065-9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Pace JK 2nd, Feschotte C. The evolutionary history of human DNA transposons: evidence for intense activity in the primate lineage. Genome Res. 2007;17(4):422–32.  https://doi.org/10.1101/gr.5826307.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bourque G, Burns KH, Gehring M, Gorbunova V, Seluanov A, Hammell M, et al. Ten things you should know about transposable elements. Genome Biol. 2018;19(1):199.  https://doi.org/10.1186/s13059-018-1577-z.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Belshaw R, Katzourakis A, Paces J, Burt A, Tristem M. High copy number in human endogenous retrovirus families is associated with copying mechanisms in addition to reinfection. Mol Biol Evol. 2005;22(4):814–7.  https://doi.org/10.1093/molbev/msi088.CrossRefPubMedGoogle Scholar
  6. 6.
    Belshaw R, Pereira V, Katzourakis A, Talbot G, Paces J, Burt A, et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci U S A. 2004;101(14):4894–9.  https://doi.org/10.1073/pnas.0307800101.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Esteki-Zadeh A, Karimi M, Straat K, Ammerpohl O, Zeitelhofer M, Jagodic M, et al. Human cytomegalovirus infection is sensitive to the host cell DNA methylation state and alters global DNA methylation capacity. Epigenetics. 2012;7(6):585–93.  https://doi.org/10.4161/epi.20075.CrossRefPubMedGoogle Scholar
  8. 8.
    Niller HH, Tarnai Z, Decsi G, Zsedenyi A, Banati F, Minarovits J. Role of epigenetics in EBV regulation and pathogenesis. Future Microbiol. 2014;9(6):747–56.  https://doi.org/10.2217/fmb.14.41.CrossRefPubMedGoogle Scholar
  9. 9.
    Brudek T, Luhdorf P, Christensen T, Hansen HJ, Moller-Larsen A. Activation of endogenous retrovirus reverse transcriptase in multiple sclerosis patient lymphocytes by inactivated HSV-1, HHV-6 and VZV. J Neuroimmunol 2007;187(1–2):147–155. doi:S0165-5728(07)00127-0 [pii] https://doi.org/10.1016/j.jneuroim.2007.04.003.
  10. 10.
    Ruprecht K, Obojes K, Wengel V, Gronen F, Kim KS, Perron H, et al. Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis. J Neuro-Oncol. 2006;12(1):65–71.  https://doi.org/10.1080/13550280600614973.CrossRefGoogle Scholar
  11. 11.
    Bergallo M, Galliano I, Montanari P, Gambarino S, Mareschi K, Ferro F, et al. CMV induces HERV-K and HERV-W expression in kidney transplant recipients. J Clin Virol. 2015;68:28–31.  https://doi.org/10.1016/j.jcv.2015.04.018.CrossRefPubMedGoogle Scholar
  12. 12.
    Charvet B, Reynaud JM, Gourru-Lesimple G, Perron H, Marche PN, Horvat B. Induction of proinflammatory multiple sclerosis-associated retrovirus envelope protein by human herpesvirus-6A and CD46 receptor engagement. Front Immunol. 2018;9:2803.  https://doi.org/10.3389/fimmu.2018.02803.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579–89.CrossRefGoogle Scholar
  14. 14.
    Mameli G, Poddighe L, Mei A, Uleri E, Sotgiu S, Serra C, et al. Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis. PLoS One. 2012;7(9):e44991.  https://doi.org/10.1371/journal.pone.0044991.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Serra C, Mameli G, Arru G, Sotgiu S, Rosati G, Dolei A. In vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: implications for MS pathogenesis. J Neuro-Oncol. 2003;9(6):637–43.  https://doi.org/10.1080/13550280390246462.CrossRefGoogle Scholar
  16. 16.
    Petersen T, Moller-Larsen A, Thiel S, Brudek T, Hansen TK, Christensen T. Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis. J Neuroimmunol. 2009;215(1–2):108–16.  https://doi.org/10.1016/j.jneuroim.2009.08.015.CrossRefPubMedGoogle Scholar
  17. 17.
    Diem O, Schaffner M, Seifarth W, Leib-Mosch C. Influence of antipsychotic drugs on human endogenous retrovirus (HERV) transcription in brain cells. PLoS One. 2012;7(1):e30054.  https://doi.org/10.1371/journal.pone.0030054.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Azebi S, Batsche E, Michel F, Kornobis E, Muchardt C. Expression of endogenous retroviruses reflects increased usage of atypical enhancers in T cells. EMBO J. 2019;38(12).  https://doi.org/10.15252/embj.2018101107.
  19. 19.
    Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: a comprehensive review. J Autoimmun. 2015;64:13–25.  https://doi.org/10.1016/j.jaut.2015.06.010.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015;14(3):263–73.  https://doi.org/10.1016/S1474-4422(14)70267-4.CrossRefPubMedGoogle Scholar
  21. 21.
    Morandi E, Tanasescu R, Tarlinton RE, Constantinescu CS, Zhang W, Tench C, et al. The association between human endogenous retroviruses and multiple sclerosis: a systematic review and meta-analysis. PLoS One. 2017;12(2):e0172415.  https://doi.org/10.1371/journal.pone.0172415.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mameli G, Astone V, Arru G, Marconi S, Lovato L, Serra C, Sotgiu S, Bonetti B, Dolei A Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not human herpesvirus 6. J Gen Virol. 2007;88(Pt 1):264–274. doi: https://doi.org/10.1099/vir.0.81890-0.CrossRefGoogle Scholar
  23. 23.
    Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, et al. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler. 2012;18(12):1721–36.  https://doi.org/10.1177/1352458512441381.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sotgiu S, Mameli G, Serra C, Zarbo IR, Arru G, Dolei A. Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler. 2010;16(10):1248–51.  https://doi.org/10.1177/1352458510376956.CrossRefPubMedGoogle Scholar
  25. 25.
    van Horssen J, van der Pol S, Nijland P, Amor S, Perron H. Human endogenous retrovirus W in brain lesions: rationale for targeted therapy in multiple sclerosis. Mult Scler Relat Disord. 2016;8:11–8.  https://doi.org/10.1016/j.msard.2016.04.006.CrossRefPubMedGoogle Scholar
  26. 26.
    •• Kremer D, Gruchot J, Weyers V, Oldemeier L, Gottle P, Healy L et al. pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. Proc Natl Acad Sci U S A. 2019;116(30):15216–15225. doi: https://doi.org/10.1073/pnas.1901283116. Provides evidence of the key role of HERV-W Env in MS pathogenesis. CrossRefGoogle Scholar
  27. 27.
    Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R. MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: relevance of GNbAC1 in multiple sclerosis treatment. J Neuroimmunol. 2016;291:29–38.  https://doi.org/10.1016/j.jneuroim.2015.12.006.CrossRefPubMedGoogle Scholar
  28. 28.
    •• Perron H, Dougier-Reynaud HL, Lomparski C, Popa I, Firouzi R, Bertrand JB, Marusic S, Portoukalian J, Jouvin-Marche E, Villiers CL, Touraine JL, Marche PN Human endogenous retrovirus protein activates innate immunity and promotes experimental allergic encephalomyelitis in mice. PLoS One 2013;8(12):e80128. doi: https://doi.org/10.1371/journal.pone.0080128. Evidences the induction of autoimmunity by HERV-W-Env toward a defined self-antigen. CrossRefGoogle Scholar
  29. 29.
    Kremer D, Schichel T, Forster M, Tzekova N, Bernard C, van der Valk P, et al. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol. 2013;74(5):721–32.  https://doi.org/10.1002/ana.23970.CrossRefPubMedGoogle Scholar
  30. 30.
    Gottle P, Forster M, Gruchot J, Kremer D, Hartung HP, Perron H, et al. Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination. Glia. 2019;67(1):160–70.  https://doi.org/10.1002/glia.23535.CrossRefPubMedGoogle Scholar
  31. 31.
    Curtin F, Perron H, Kromminga A, Porchet H, Lang AB. Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. MAbs. 2015;7(1):265–75.  https://doi.org/10.4161/19420862.2014.985021.CrossRefPubMedGoogle Scholar
  32. 32.
    Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93(11):1617–28.  https://doi.org/10.1016/j.mayocp.2018.04.007.CrossRefPubMedGoogle Scholar
  33. 33.
    Yu B, Pamphlett R. Environmental insults: critical triggers for amyotrophic lateral sclerosis. Transl Neurodegener. 2017;6:15.  https://doi.org/10.1186/s40035-017-0087-3.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69(1):141–51.  https://doi.org/10.1002/ana.22149.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Li W, Lee MH, Henderson L, Tyagi R, Bachani M, Steiner J, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7(307):307ra153.  https://doi.org/10.1126/scitranslmed.aac8201.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Manghera M, Ferguson-Parry J, Lin R, Douville RN. NF-kappaB and IRF1 induce endogenous retrovirus K expression via interferon-stimulated response elements in its 5′ long terminal repeat. J Virol. 2016;90(20):9338–49.  https://doi.org/10.1128/JVI.01503-16.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Gonzalez-Hernandez MJ, Swanson MD, Contreras-Galindo R, Cookinham S, King SR, Noel RJ Jr, et al. Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1. J Virol. 2012;86(15):7790–805.  https://doi.org/10.1128/JVI.07215-11.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Baggen J, Thibaut HJ, Strating J, van Kuppeveld FJM. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368–81.  https://doi.org/10.1038/s41579-018-0005-4.CrossRefPubMedGoogle Scholar
  39. 39.
    Hodik M, Anagandula M, Fuxe J, Krogvold L, Dahl-Jorgensen K, Hyoty H, et al. Coxsackie-adenovirus receptor expression is enhanced in pancreas from patients with type 1 diabetes. BMJ Open Diabetes Res Care. 2016;4(1):e000219.  https://doi.org/10.1136/bmjdrc-2016-000219.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Ifie E, Russell MA, Dhayal S, Leete P, Sebastiani G, Nigi L, et al. Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia. 2018;61(11):2344–55.  https://doi.org/10.1007/s00125-018-4704-1.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia. 2013;56(1):185–93.  https://doi.org/10.1007/s00125-012-2745-4.CrossRefPubMedGoogle Scholar
  42. 42.
    Krogvold L, Edwin B, Buanes T, Frisk G, Skog O, Anagandula M, et al. Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes. 2015;64(5):1682–7.  https://doi.org/10.2337/db14-1370.CrossRefPubMedGoogle Scholar
  43. 43.
    Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ. 2011;342:d35.  https://doi.org/10.1136/bmj.d35.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Alidjinou EK, Sane F, Lefevre C, Baras A, Moumna I, Engelmann I, et al. Enteroviruses in blood of patients with type 1 diabetes detected by integrated cell culture and reverse transcription quantitative real-time PCR. Acta Diabetol. 2017;54(11):1025–9.  https://doi.org/10.1007/s00592-017-1041-7.CrossRefPubMedGoogle Scholar
  45. 45.
    Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia. 2009;52(6):1143–51.  https://doi.org/10.1007/s00125-009-1276-0.CrossRefPubMedGoogle Scholar
  46. 46.
    Looney BM, Xia CQ, Concannon P, Ostrov DA, Clare-Salzler MJ. Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDA5 function and expression. Curr Diab Rep. 2015;15(11):96.  https://doi.org/10.1007/s11892-015-0656-8.CrossRefPubMedGoogle Scholar
  47. 47.
    Richardson SJ, Rodriguez-Calvo T, Gerling IC, Mathews CE, Kaddis JS, Russell MA, et al. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia. 2016;59(11):2448–58.  https://doi.org/10.1007/s00125-016-4067-4.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Bian X, Wallstrom G, Davis A, Wang J, Park J, Throop A, et al. Immunoproteomic profiling of antiviral antibodies in new-onset type 1 diabetes using protein arrays. Diabetes. 2016;65(1):285–96.  https://doi.org/10.2337/db15-0179.CrossRefPubMedGoogle Scholar
  49. 49.
    •• Rodriguez-Calvo T. Enterovirus infection and type 1 diabetes: unraveling the crime scene. Clin Exp Immunol. 2019;195(1):15–24. doi: https://doi.org/10.1111/cei.13223. A recent review on the involvement of enteroviruses in T1D. CrossRefGoogle Scholar
  50. 50.
    •• Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol 2010;6(5):279–89. doi: https://doi.org/10.1038/nrendo.2010.27. An overview of the role of enteroviruses in T1D. CrossRefGoogle Scholar
  51. 51.
    Chehadeh W, Kerr-Conte J, Pattou F, Alm G, Lefebvre J, Wattre P, et al. Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in beta cells. J Virol. 2000;74(21):10153–64.  https://doi.org/10.1128/jvi.74.21.10153-10164.2000.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Hodik M, Skog O, Lukinius A, Isaza-Correa JM, Kuipers J, Giepmans BN, et al. Enterovirus infection of human islets of Langerhans affects beta-cell function resulting in disintegrated islets, decreased glucose stimulated insulin secretion and loss of Golgi structure. BMJ Open Diabetes Res Care. 2016;4(1):e000179.  https://doi.org/10.1136/bmjdrc-2015-000179.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Colli ML, Nogueira TC, Allagnat F, Cunha DA, Gurzov EN, Cardozo AK, et al. Exposure to the viral by-product dsRNA or Coxsackievirus B5 triggers pancreatic beta cell apoptosis via a Bim / Mcl-1 imbalance. PLoS Pathog. 2011;7(9):e1002267.  https://doi.org/10.1371/journal.ppat.1002267.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Alidjinou EK, Engelmann I, Bossu J, Villenet C, Figeac M, Romond MB, et al. Persistence of Coxsackievirus B4 in pancreatic ductal-like cells results in cellular and viral changes. Virulence. 2017;8(7):1229–44.  https://doi.org/10.1080/21505594.2017.1284735.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    •• Engelmann I, Alidjinou EK, Bertin A, Bossu J, Villenet C, Figeac M et al. Persistent coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic cells. Cell Mol Life Sci. 2017;74(20):3851–61. doi: https://doi.org/10.1007/s00018-017-2567-0. The impact of a persistent CV-B4 infection on miRNA in human pancreatic cells. CrossRefGoogle Scholar
  56. 56.
    Alidjinou EK, Chehadeh W, Weill J, Vantyghem MC, Stuckens C, Decoster A, et al. Monocytes of patients with type 1 diabetes harbour Enterovirus RNA. Eur J Clin Investig. 2015;45(9):918–24.  https://doi.org/10.1111/eci.12485.CrossRefGoogle Scholar
  57. 57.
    Alidjinou EK, Sane F, Trauet J, Copin MC, Hober D. Coxsackievirus B4 can infect human peripheral blood-derived macrophages. Viruses. 2015;7(11):6067–79.  https://doi.org/10.3390/v7112924.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    •• Benkahla MA, Elmastour F, Sane F, Vreulx AC, Engelmann I, Desailloud R et al. Coxsackievirus-B4E2 can infect monocytes and macrophages in vitro and in vivo. Virology. 2018;522:271–80. doi: https://doi.org/10.1016/j.virol.2018.06.010. This study shows that CV-B4 can infect macorphages in vivo. CrossRefGoogle Scholar
  59. 59.
    Lombardi A, Tomer Y. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. J Autoimmun. 2017;80:48–55.  https://doi.org/10.1016/j.jaut.2017.02.002.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Jean-Baptiste VSE, Xia CQ, Clare-Salzler MJ, Horwitz MS. Type 1 diabetes and type 1 interferonopathies: localization of a type 1 common thread of virus infection in the pancreas. EBioMedicine. 2017;22:10–7.  https://doi.org/10.1016/j.ebiom.2017.06.014.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Sozzani S, Del Prete A, Bosisio D. Dendritic cell recruitment and activation in autoimmunity. J Autoimmun. 2017;85:126–40.  https://doi.org/10.1016/j.jaut.2017.07.012.CrossRefPubMedGoogle Scholar
  62. 62.
    •• Hober D, Sane F, Jaidane H, Riedweg K, Goffard A, Desailloud R. Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes. Clin Exp Immunol 2012;168(1):47–51. doi: https://doi.org/10.1111/j.1365-2249.2011.04559.x. Evidence of the pathogenic role of facilitating antibodies against Coxsackievirus-B. CrossRefGoogle Scholar
  63. 63.
    Goffard A, Alidjinou EK, Sane F, Choteau L, Bouquillon C, Caloone D, et al. Antibodies enhance the infection of phorbol-ester-differentiated human monocyte-like cells with coxsackievirus B4. Microbes Infect. 2013;15(1):18–27.  https://doi.org/10.1016/j.micinf.2012.10.005.CrossRefPubMedGoogle Scholar
  64. 64.
    Sauter P, Chehadeh W, Lobert PE, Lazrek M, Goffard A, Soumillon M, et al. A part of the VP4 capsid protein exhibited by coxsackievirus B4 E2 is the target of antibodies contained in plasma from patients with type 1 diabetes. J Med Virol. 2008;80(5):866–78.  https://doi.org/10.1002/jmv.21171.CrossRefPubMedGoogle Scholar
  65. 65.
    Sauter P, Lobert PE, Lucas B, Varela-Calvino R, Alm G, Wattre P, et al. Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells. Virus Res. 2007;125(2):183–90.  https://doi.org/10.1016/j.virusres.2007.01.001.CrossRefPubMedGoogle Scholar
  66. 66.
    Alidjinou EK, Sane F, Engelmann I, Hober D. Serum-dependent enhancement of coxsackievirus B4-induced production of IFNalpha, IL-6 and TNFalpha by peripheral blood mononuclear cells. J Mol Biol. 2013;425(24):5020–31.  https://doi.org/10.1016/j.jmb.2013.10.008.CrossRefPubMedGoogle Scholar
  67. 67.
    Hober D, Chehadeh W, Weill J, Hober C, Vantyghem MC, Gronnier P, et al. Circulating and cell-bound antibodies increase coxsackievirus B4-induced production of IFN-alpha by peripheral blood mononuclear cells from patients with type 1 diabetes. J Gen Virol. 2002;83(Pt 9:2169–76.  https://doi.org/10.1099/0022-1317-83-9-2169.CrossRefPubMedGoogle Scholar
  68. 68.
    Sauter P, Hober D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect. 2009;11(4):443–51.CrossRefGoogle Scholar
  69. 69.
    Elmastour F, Jaidane H, Aguech-Oueslati L, Benkahla MA, Aouni M, Gharbi J, et al. Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system. Virulence. 2016;7(5):527–35.  https://doi.org/10.1080/21505594.2016.1152442.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Elmastour F, Jaidane H, Benkahla M, Aguech-Oueslati L, Sane F, Halouani A, et al. Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4. Virulence. 2017;8(6):908–23.  https://doi.org/10.1080/21505594.2016.1252018.CrossRefPubMedGoogle Scholar
  71. 71.
    DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449–62.  https://doi.org/10.1016/S0140-6736(18)31320-5.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Suenaga K, Yoon JW. Association of beta-cell-specific expression of endogenous retrovirus with development of insulitis and diabetes in NOD mouse. Diabetes. 1988;37(12):1722–6.  https://doi.org/10.2337/diab.37.12.1722.CrossRefPubMedGoogle Scholar
  73. 73.
    Gaskins HR, Prochazka M, Hamaguchi K, Serreze DV, Leiter EH. Beta cell expression of endogenous xenotropic retrovirus distinguishes diabetes-susceptible NOD/Lt from resistant NON/Lt mice. J Clin Invest. 1992;90(6):2220–7.  https://doi.org/10.1172/JCI116107.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Tsumura H, Miyazawa M, Ogawa S, Wang JZ, Ito Y, Shimura K. Detection of endogenous retrovirus antigens in NOD mouse pancreatic beta-cells. Lab Anim. 1998;32(1):86–94.  https://doi.org/10.1258/002367798780559464.CrossRefPubMedGoogle Scholar
  75. 75.
    •• Bashratyan R, Regn D, Rahman MJ, Marquardt K, Fink E, Hu WY et al. Type 1 diabetes pathogenesis is modulated by spontaneous autoimmune responses to endogenous retrovirus antigens in NOD mice. Eur J Immunol. 2017;47(3):575–84. doi: https://doi.org/10.1002/eji.201646755. Recent confirmation of the involvement of an endogenous retrovirus in T1D NOD-mouse model. CrossRefGoogle Scholar
  76. 76.
    Mason MJ, Speake C, Gersuk VH, Nguyen QA, O’Brien KK, Odegard JM, et al. Low HERV-K(C4) copy number is associated with type 1 diabetes. Diabetes. 2014;63(5):1789–95.  https://doi.org/10.2337/db13-1382.CrossRefPubMedGoogle Scholar
  77. 77.
    Armezzani A, Varela M, Spencer TE, Palmarini M, Arnaud F. “Menage a trois”: the evolutionary interplay between JSRV, enJSRVs and domestic sheep. Viruses. 2014;6(12):4926–45.  https://doi.org/10.3390/v6124926.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Niegowska M, Wajda-Cuszlag M, Stepien-Ptak G, Trojanek J, Michalkiewicz J, Szalecki M, et al. Anti-HERV-WEnv antibodies are correlated with seroreactivity against Mycobacterium avium subsp. paratuberculosis in children and youths at T1D risk. Sci Rep. 2019;9(1):6282.  https://doi.org/10.1038/s41598-019-42788-5.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Marguerat S, Wang WY, Todd JA, Conrad B. Association of human endogenous retrovirus K-18 polymorphisms with type 1 diabetes. Diabetes. 2004;53(3):852–4.  https://doi.org/10.2337/diabetes.53.3.852.CrossRefPubMedGoogle Scholar
  80. 80.
    Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell. 1997;90(2):303–13.CrossRefGoogle Scholar
  81. 81.
    Jaeckel E, Heringlake S, Berger D, Brabant G, Hunsmann G, Manns MP. No evidence for association between IDDMK(1,2)22, a novel isolated retrovirus, and IDDM. Diabetes. 1999;48(1):209–14.CrossRefGoogle Scholar
  82. 82.
    Kim A, Jun HS, Wong L, Stephure D, Pacaud D, Trussell RA, et al. Human endogenous retrovirus with a high genomic sequence homology with IDDMK(1,2)22 is not specific for type I (insulin-dependent) diabetic patients but ubiquitous. Diabetologia. 1999;42(4):413–8.  https://doi.org/10.1007/s001250051173.CrossRefPubMedGoogle Scholar
  83. 83.
    Muir A, Ruan QG, Marron MP, She JX. The IDDMK(1,2)22 retrovirus is not detectable in either mRNA or genomic DNA from patients with type 1 diabetes. Diabetes. 1999;48(1):219–22.CrossRefGoogle Scholar
  84. 84.
    Ramos-Lopez E, Ghebru S, Van Autreve J, Aminkeng F, Herwig J, Seifried E, et al. Neither an intronic CA repeat within the CD48 gene nor the HERV-K18 polymorphisms are associated with type 1 diabetes. Tissue Antigens. 2006;68(2):147–52.  https://doi.org/10.1111/j.1399-0039.2006.00637.x.CrossRefPubMedGoogle Scholar
  85. 85.
    Perron H, Lalande B, Gratacap B, Laurent A, Genoulaz O, Geny C, et al. Isolation of retrovirus from patients with multiple sclerosis. Lancet. 1991;337(8745):862–3.CrossRefGoogle Scholar
  86. 86.
    Perron H, Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol. 2010;39(1):51–61.  https://doi.org/10.1007/s12016-009-8170-x.CrossRefPubMedGoogle Scholar
  87. 87.
    •• Levet S, Medina J, Joanou J, Demolder A, Queruel N, Reant K et al. An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes. JCI Insight 2017;2(17). doi: https://doi.org/10.1172/jci.insight.94387. First study evidencing the detection and the pathogenic properties of HERV-W Env in T1D.
  88. 88.
    Garay-Malpartida HM, Mourao RF, Mantovani M, Santos IA, Sogayar MC, Goldberg AC. Toll-like receptor 4 (TLR4) expression in human and murine pancreatic beta-cells affects cell viability and insulin homeostasis. BMC Immunol. 2011;12:18.  https://doi.org/10.1186/1471-2172-12-18.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Amyot J, Semache M, Ferdaoussi M, Fontes G, Poitout V. Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-like receptor-4 and NF-kappaB signalling. PLoS One. 2012;7(4):e36200.  https://doi.org/10.1371/journal.pone.0036200.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab. 2008;93(2):578–83.  https://doi.org/10.1210/jc.2007-2185.CrossRefPubMedGoogle Scholar
  91. 91.
    Duperray A, Barbe D, Raguenez G, Weksler BB, Romero IA, Couraud PO, et al. Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. Int Immunol. 2015;27(11):545–53.  https://doi.org/10.1093/intimm/dxv025.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Faucard R, Madeira A, Gehin N, Authier FJ, Panaite PA, Lesage C, et al. Human endogenous retrovirus and neuroinflammation in chronic inflammatory demyelinating Polyradiculoneuropathy. EBioMedicine. 2016;6:190–8.  https://doi.org/10.1016/j.ebiom.2016.03.001.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol. 2006;176(12):7636–44.CrossRefGoogle Scholar
  94. 94.
    Saresella M, Rolland A, Marventano I, Cavarretta R, Caputo D, Marche P, et al. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009;15(4):443–7.  https://doi.org/10.1177/1352458508100840.CrossRefPubMedGoogle Scholar
  95. 95.
    Perron H, Jouvin-Marche E, Michel M, Ounanian-Paraz A, Camelo S, Dumon A, et al. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology. 2001;287(2):321–32.  https://doi.org/10.1006/viro.2001.1045.CrossRefPubMedGoogle Scholar
  96. 96.
    •• Thomas J, Perron H, Feschotte C. Variation in proviral content among human genomes mediated by LTR recombination. Mob DNA 2018;9:36. doi: https://doi.org/10.1186/s13100-018-0142-3. Evidence of heterogeneous distribution of genomic copies from different HERV families across genomes of human individuals.
  97. 97.
    Tettey P, Simpson S Jr, Taylor BV, van der Mei IA. The co-occurrence of multiple sclerosis and type 1 diabetes: shared aetiologic features and clinical implication for MS aetiology. J Neurol Sci. 2015;348(1–2):126–31.  https://doi.org/10.1016/j.jns.2014.11.019.CrossRefPubMedGoogle Scholar
  98. 98.
    Curtin F, Bernard C, Levet S, Perron H, Porchet H, Medina J, et al. A new therapeutic approach for type 1 diabetes: rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody. Diabetes Obes Metab. 2018;20(9):2075–84.  https://doi.org/10.1111/dom.13357.CrossRefPubMedGoogle Scholar
  99. 99.
    Curtin F, Perron H, Faucard R, Porchet H, Lang AB. Treatment against human endogenous retrovirus: a possible personalized medicine approach for multiple sclerosis. Mol Diagn Ther. 2015;19(5):255–65.  https://doi.org/10.1007/s40291-015-0166-z.CrossRefPubMedGoogle Scholar
  100. 100.
    Kury P, Nath A, Creange A, Dolei A, Marche P, Gold J, et al. Human endogenous retroviruses in neurological diseases. Trends Mol Med. 2018;24(4):379–94.  https://doi.org/10.1016/j.molmed.2018.02.007.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Sandrine Levet
    • 1
    Email author
  • B. Charvet
    • 1
  • A. Bertin
    • 2
  • A. Deschaumes
    • 2
  • H. Perron
    • 1
    • 3
    • 4
  • D. Hober
    • 2
  1. 1.GeNeuro InnovationLyonFrance
  2. 2.Faculté de Médecine, CHU Lille, Laboratoire de Virologie EA3610Université LilleLilleFrance
  3. 3.Laboratoire des déficits immunitairesUniversity of LyonLyonFrance
  4. 4.Plan-les-OuatesGeNeuro SAGenevaSwitzerland

Personalised recommendations